Download PDF
Drug Res (Stuttg) 2017; 67(03): 170-178
DOI: 10.1055/s-0042-120116
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

C6- and C7-Substituted 3,4-dihydro-2(1H)-quinolinones as Inhibitors of Monoamine Oxidase

Letitia Meiring
1   Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
,
Jacobus Petrus Petzer
1   Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
,
Anél Petzer
1   Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
› Author Affiliations
Further Information

Publication History

received 26 August 2016

accepted 31 October 2016

Publication Date:
07 December 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Purpose Monoamine oxidase (MAO) inhibitors are considered to be useful therapeutic agents and isoform specific inhibitors are employed for the treatment of depression and Parkinson’s disease. MAO inhibitors are also under investigation for the treatment of disorders ranging from Alzheimer’s disease, prostate cancer and certain cardiomyopathies. While a number of irreversible MAO inhibitors are available in the clinic, reversible inhibitors, particularly of the MAO-B isoform are still being developed. Based on our interest in discovering reversible inhibitors with specificity for MAO-B, we have recently reported that, among a series of 10 3,4-dihydro-2(1H)-quinolinone derivatives, are high potency MAO-B inhibitors, with a number of homologues displaying good selectivities for MAO-B over the MAO-A isoform.

Methods and Findings: To expand on these promising findings and to derive structure-activity relationships, the current study synthesizes a series of 14 3,4-dihydro-2(1H)-quinolinone derivatives. An evaluation of their MAO inhibition properties shows that all derivatives are MAO-B specific with the most potent inhibitor (3a) displaying an IC50 value of 0.0014 µM. Selectivities for MAO-B ranged from 99 to 40 000-fold.

Conclusions: It may thus be concluded that substitution of 3,4-dihydro-2(1H)-quinolinone on C6 and C7 with a variety of side chains yields highly potent and selective MAO-B inhibitors, compounds with existing and prospective therapeutic applications.

 

  • References

  • 1 Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309
    CrossrefPubMedGoogle Scholar
  • 2 Schwartz TL. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr 2013; 18 (Suppl. 01) 25-32
    PubMedGoogle Scholar
  • 3 Lum CT, Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr 2012; 17: 107-120
    CrossrefPubMedGoogle Scholar
  • 4 Shoulson I, Oakes D, Fahn S et al. Parkinson Study Group . Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604-612
    CrossrefPubMedGoogle Scholar
  • 5 Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy 2007; 27: 174S-185S
    CrossrefPubMedGoogle Scholar
  • 6 Finberg JP, Wang J, Bankiewicz K et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 1998; 52: 279-285
    PubMedGoogle Scholar
  • 7 Da Prada M, Zürcher G, Wüthrich I et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988; 26: 31-56
    PubMedGoogle Scholar
  • 8 Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry 2012; 73 (Suppl. 01) 17-24
    CrossrefPubMedGoogle Scholar
  • 9 Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 2011; 100: 169-190
    PubMedGoogle Scholar
  • 10 Lasbennes F, Sercombe R, Seylaz J. Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: relevance to the blood-brain barrier. J Cereb Blood Flow Metab 1983; 3: 521-528
    CrossrefPubMedGoogle Scholar
  • 11 Finberg JP, Lamensdorf I, Armoni T. Modification of dopamine release by selective inhibitors of MAO-B. Neurobiology (Bp) 2000; 8: 137-142
    PubMedGoogle Scholar
  • 12 Janssen PA, Leysen JE, Megens AA et al. Does phenylethylamine act as an endogenous amphetamine in some patients?. Int J Neuropsychopharmacol 1999; 2: 229-240
    CrossrefPubMedGoogle Scholar
  • 13 Chiba K, Trevor A, Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120: 574-578
    CrossrefPubMedGoogle Scholar
  • 14 Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 2006; 147 (Suppl. 01) S287-S296
    PubMedGoogle Scholar
  • 15 Edmondson DE. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr Pharm Des 2014; 20: 155-160
    CrossrefPubMedGoogle Scholar
  • 16 Fowler JS, Volkow ND, Wang GJ et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997; 18: 431-435
    CrossrefPubMedGoogle Scholar
  • 17 Maurel A, Hernandez C, Kunduzova O et al. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 2003; 284: H1460-H1467
    CrossrefPubMedGoogle Scholar
  • 18 Xu S, Adisetiyo H, Tamura S et al. Dual inhibition of survivin and MAO A synergistically impairs growth of PTEN-negative prostate cancer. Br J Cancer 2015; 113: 242-251
    CrossrefPubMedGoogle Scholar
  • 19 Wu JB, Shao C, Li X et al. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest 2014; 124: 2891-2908
    CrossrefPubMedGoogle Scholar
  • 20 Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. J Med Chem 2015; 58: 6717-6732
    CrossrefPubMedGoogle Scholar
  • 21 Carradori S, Petzer JP. Novel monoamine oxidase inhibitors: a patent review (2012–2014). Expert Opin Ther Pat 2015; 25: 91-110
    CrossrefPubMedGoogle Scholar
  • 22 Gnerre C, Catto M, Leonetti F et al. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem 2000; 43: 4747-4758
    CrossrefPubMedGoogle Scholar
  • 23 Meiring L, Petzer JP, Petzer A. Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives. Bioorg Med Chem Lett 2013; 23: 5498-5502
    CrossrefPubMedGoogle Scholar
  • 24 Mostert S, Petzer A, Petzer JP. Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem 2015; 10: 862-873
    CrossrefPubMedGoogle Scholar
  • 25 Mostert S, Petzer A, Petzer JP. Inhibition of monoamine oxidase by benzoxathiolone analogues. Bioorg Med Chem Lett 2016; 26: 1200-1204
    CrossrefPubMedGoogle Scholar
  • 26 Novaroli L, Reist M, Favre E et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem 2005; 13: 6212-6217
    CrossrefPubMedGoogle Scholar
  • 27 Petzer A, Harvey BH, Wegener G et al. a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 2012; 258: 403-409
    CrossrefPubMedGoogle Scholar
  • 28 Accelrys Discovery Studio 3.1. San Diego, CA, USA: Accelrys Software Inc; 2005. http://www.accelrys.com
    Google Scholar
  • 29 Son SY, Ma J, Kondou Y et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A 2008; 105: 5739-5744
    CrossrefPubMedGoogle Scholar
  • 30 Binda C, Wang J, Pisani L et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007; 50: 5848-5852
    CrossrefPubMedGoogle Scholar
  • 31 DeLano WL. 2002. The PyMOL molecular graphics system. San Carlos, USA: DeLano Scientific;
    Google Scholar
  • 32 Shigematsu N. Studies on the synthetic analgesics. XVI. Synthesis of 1-(2-tert-aminoalkyl)-3, 4-dihydrocarbostyrils. Chem Pharm Bull 1961; 9: 970-975
    CrossrefPubMedGoogle Scholar
  • 33 Sun XY, Zhang L, Wei CX et al. Design, synthesis of 8-alkoxy-5,6-dihydro-[1,2,4]triazino[4,3-a]quinolin-1-ones with anticonvulsant activity. Eur J Med Chem 2009; 44: 1265-1270
    CrossrefPubMedGoogle Scholar
  • 34 Strydom B, Bergh JJ, Petzer JP. The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy)caffeine analogues. Arzneimittel-Forsch 2012; 62: 513-518
    PubMedGoogle Scholar
  • 35 Petzer A, Pienaar A, Petzer JP. The inhibition of monoamine oxidase by esomeprazole. Arzneimittel-Forsch 2013; 63: 462-467
    PubMedGoogle Scholar
  • 36 Mathew B, Haridas A, Uçar G et al. Exploration of chlorinated thienyl chalcones: A new class of monoamine oxidase-B inhibitors. Int J Biol Macromol 2016; 91: 680-695
    CrossrefPubMedGoogle Scholar
  • 37 Hammuda A, Shalaby R, Rovida S et al. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Eur J Med Chem 2016; 114: 162-169
    CrossrefPubMedGoogle Scholar